Table 1.
Patient and disease characteristics (N = 142)
| Number | Percent | |
|---|---|---|
| Age at start of anti-PD-1/PD-L1 therapy | ||
| < 60 | 58 | 40.8 |
| ≥ 60 | 84 | 59.2 |
| Smoker | ||
| No | 69 | 48.6 |
| Yes | 72 | 50.7 |
| Unknown | 1 | 0.7 |
| Gender | ||
| Female | 41 | 28.9 |
| Male | 101 | 71.1 |
| Histology | ||
| Clear cell RCC | 120 | 84.5 |
| Non-clear cell RCC | 22 | 15.5 |
| Presence of Sarcomatoid | ||
| No | 119 | 83.8 |
| Yes | 22 | 15.5 |
| Unknown | 1 | 0.7 |
| Presence of Rhabdoid | ||
| No | 134 | 94.4 |
| Yes | 6 | 4.2 |
| Unknown | 2 | 1.4 |
| IMDC risk group at start of anti-PD-1/PD-L1 therapy | ||
| Favorable | 26 | 18.3 |
| Intermediate | 85 | 59.9 |
| Poor | 31 | 21.8 |
| Line of therapy | ||
| 1 | 62 | 43.7 |
| 2 | 37 | 26.1 |
| ≥ 3 | 43 | 30.3 |
| Type of anti-PD-1/PD-L1 therapy | ||
| Monotherapy | 76 | 53.5 |
| Combination therapy PD-L1 + VEGF targeted therapy (n = 46) PD-1 + VEGF-targeted therapy (n = 9) PD-1 + CTLA-4 (n = 7) PD-1 + other (n = 4) |
66 | 46.5 |
| Median | range | |
| NLR - baseline | 3.9 | 1.3–42.4 |
| NLR - week 6 | 4.1 | 1.1–96.4 |